PDLabs is a compounding and research pharmacy established in 1998 to research and develop new indications for existing medications and to develop new drug delivery systems.
PDLabs’ most significant discovery and contribution to pharmacotherapy to date relates to the use of calcium channel blockers for the non-invasive, topically applied transdermal treatment of connective tissue disorders. This includes, but is not limited to, Peyronie’s disease, Dupuytren’s disease and plantar fibromatosis. Plans are currently underway to obtain United States Food and Drug Administration (FDA) approval for several indications.
PDLabs does not fill prescriptions based solely on a questionnaire or telephone conversation. All patients provided prescription medication from PDLabs must receive an exam by a qualified physician who will be available to discuss a patient’s condition with one of PDLabs’ pharmacists if needed. PDLabs takes an active role in the care of every patient with regular patient follow-ups and correspondence with each patient’s physician when necessary. Positive treatment outcomes are improved when the patient, physician, and pharmacist work closely together.
PDLabs does not make any claims, overt or implied, of the safety or effectiveness of any medication it compounds. It will refer only to references pertaining to peer reviewed medical publications and/or safety studies endorsed by the FDA.
In keeping with FDA regulations, PDLabs’ intentions are to provide pertinent and informative facts and information that will assist a person in making a well informed and educated decision about his/her medical care.
PDLabs maintains all patient information in strict confidence according to the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA). Patient confidentiality is protected at all costs.